(2E,4E,6Z,8E)-3-Methyl-7-(p-tolyl)-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
rel-5-((1S,3aR,4R,6aR)-4-(3,4-Dimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan-1-yl)benzo[d][1,3]dioxole
1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
Methyllinderone
8-Methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
Torilin
Pnri-299
Ganoderic acid H
Fas C-Terminal Tripeptide
(E)-2-((4,5-Dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methylene)undecanoic acid
1-((5-Methoxy-2-(thiophen-2-yl)quinazolin-4-yl)amino)-3-methyl-1H-pyrrole-2,5-dione
1-[(2-Chlorophenyl)methyl]-5'-phenyl-1,2-dihydro-3'H-spiro[indole-3,2'-[1,3,4]thiadiazol]-2-one
INI-43
(S)-(1R,2R,3R,3aS,3a1S,4R,6aR,7aS,11S,11aS,11bR)-1,2,11-Trihydroxy-3,8,11a-trimethyl-5,10-dioxo-2,3,3a,4,5,6a,7,7a,10,11,11a,11b-dodecahydro-1H-1,3a1-(epoxymethano)dibenzo[de,g]chromen-4-yl 2-hydroxy-2-methylbutanoate
(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(6-((3-hydroxyphenyl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diyl diacetate
SSAO/VAP-1 inhibitor 1
Glucocorticoid receptor modulator 1
